| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Research Abstract |
Histone deacetylase(HDAC) inhibitors are new class drug for cutaneous T cell lymphoma. However, the majority of patients will eventually develop resistance. To clarify the mechanisms of acquired resistance to HDAC inhibitor, we established the acquired resistant cell lines against valproic acid, from 5 individual cell lines. IC50 values of these sublines were more than 2-fold resistant to not only valproic acid but vorinostat, compared to their parent cell lines. HDAC inhibitor-induced apoptosis were diminished in all 5 sub-lined compared to their own counterpart.
|
